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Research article 
Memantine increases NMDA receptor level in the prefrontal cortex 
but fails to reverse apomorphine-induced conditioned place 
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Abstract: Studies have shown that inflammation and neurodegeneration may accompany the 
development of addiction to apomorphine and that the glutamate NMDA receptor antagonist, 
memantine, may be neuroprotective. The similarity between apomorphine and dopamine with regard 
to their chemical, pharmacological and toxicological properties provided a basis for investigating the 
mechanism of action of the former agent. In this study, we investigated whether memantine would 
suppress apomorphine-seeking behavior in rats subjected to apomorphine-induced place preference 
conditioning, through modulation of NMDA receptors in the prefrontal cortex. Repeated 
apomorphine (1 mg/kg) treatment induced conditioned place preference (CPP) and had no significant 
effect on NMDA receptor levels in the prefrontal cortex. Prior treatment with memantine  
(5 mg/kg or 10 mg/kg) increased the levels of NMDA receptors in the prefrontal cortex but did not 
suppress CPP induced by apomorphine. These data give further support to the addictive effect of 
apomorphine and demonstrate that blockade of NMDA receptors by memantine is unable to 
suppress apomorphine-seeking behavior. 
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1. Introduction 
The risk of development of addictive behavior as a side effect of many pharmacological 
therapies for psychiatric disorders, has increased in the last two decades and represents a serious 
problem in our societies today [1]. Among these drugs is apomorphine, a non-narcotic derivate of 
morphine, which acts as a dopamine receptor agonist to produce psychostimulant-like effects [2]. 
Apomorphine is prescribed as a treatment for alcohol and narcotic abuse, it is advocated as an 
antiparkinsonian agent [3] and has recently been proposed as a potential treatment for Alzheimer’s 
disease [3,4]. However, accumulated clinical evidence indicates that chronic treatment with 
apomorphine leads to addiction [5]. Indeed, a series of animal studies have supported a rewarding 
effect of apomorphine when tested in a conditioned place preference (CPP) paradigm [2,6,7]. These 
observations are not surprising as apomorphine and dopamine share structural and functional 
similarities. Apomorphine is in many respects considered a lipophilic dopamine with a catechol 
moiety [8]. Similar to dopamine, apomorphine can undergo rapid auto-oxidation to quinones [9], 
generating reactive chemical species that may be toxic to neurons [10]. 
Thus, the development of pharmacological agents that may suppress the rewarding effects of 
apomorphine, is important for its continuing therapeutic use. In this regard, one potential target 
system is the glutamatergic system. Glutamate is a neurotransmitter central to learning and 
neuroplasticity, phenomena that have been positively linked to addiction processes within the 
limbic-cortico-striato-cortical circuit [11,12]. Morphological studies support the existence of axon-axon 
synapses of glutamate and dopamine neurons in the medial PFC, ventral striatum and NAcc 
providing evidence at the synaptic level for interactions between these two neurotransmitters [13]. 
Collectively these findings provide both an anatomical and functional basis for a role for glutamate 
in addiction and therefore support initiatives that investigate its contribution to the development of 
substance use disorders. 
Memantine, a non-competitive glutamate NMDA receptor antagonist has been shown to inhibit 
the expression of CPP induced in animals with several drugs that are abused by humans such as 
cocaine and morphine at doses of 10 mg/kg, i.p. [14]. It has also been demonstrated that memantine 
at 5 mg/kg, i.p. protects inflammation-related degeneration of dopamine neurons [14,15]. These 
beneficial effects of memantine might be related to the fact that dopamine release in appetitive 
behaviors and drug abuse, requires glutamatergic input, activation of NMDA receptors, an opening 
of high-threshold calcium currents, and finally activation of calcium-activated potassium currents to 
terminate the burst of neuronal firing [16]. 
The aim of the present study was therefore to investigate the potential beneficial effect of 
memantine in apomorphine-induced reward-related behavior. We analyzed the rewarding effects of 
apomorphine using a rat place preference conditioning paradigm. We also assessed the impact of 
apomorphine and memantine on the glutamatergic system by determining its effects on the level of 
NMDA receptors in the prefrontal cortex. We focussed on this brain region as it appears to be central 
to the effects of both dopamine and glutamate in their regulation of emotional responses, cognitive 
control, and executive functions [17]. 
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2. Materials and methods 
2.1. Animals 
A total of 40 adult male Sprague-Dawley (SD) rats weighing between 180–250 g were used in 
this study. The animals were housed in groups of four per cage, with free access to food and water. 
The animals were kept at a constant temperature (21–23 °C) under a 12/12 h light-dark cycle (lights 
on at 06:00). Animals were tested during the light phase. Before starting the experiment, rats were 
accustomed to various handling procedures in order to nullify the psychological effect of environment. 
2.2. Treatment procedure 
The rats were divided into 5 groups (n = 8 each) and received the following treatments: Saline 
group (Sal/Sal) was given a daily subcutaneous injection of saline, twice a day, for 5 days followed 
by 2 days of withdrawal for 3 successive weeks. During the third week, the subcutaneous injections 
were preceded (30 min) by an i.p. injection of saline. The apomorphine group (Apo/Sal) was given a 
daily subcutaneous injection of 1 mg/kg of apomorphine and saline for 5 days followed by 2 days of 
withdrawal for 3 successive weeks. During the last week saline was injected i.p. 30 min prior to 
apomorphine administration. The memantine (Mem5/Sal) group was given a daily subcutaneous 
injection of saline for 5 days followed by 2 days of withdrawal for 3 successive weeks. During the 
last week, memantine 5 mg/kg was injected i.p. 30 min prior to saline. The two apomorphine-memantine 
(Apo/Mem5 and Apo/Mem10) groups were given a daily subcutaneous injection of 1 mg/kg of 
apomorphine for 5 days followed by 2 days of withdrawal for 3 successive weeks. During the third 
week, memantine 5 mg/kg or 10 mg/kg was given i.p. 30 min prior to apomorphine. The protocol for 
the administration of the various drugs is depicted in Figure 1. 
 
Figure 1. Timeline of the 3 phases of the conditioned place preference protocol  
(Apo: apomorphine (1 mg/kg); Sal: saline (Nacl0.9%); Mem5: Memantine (5 mg/kg); 
Mem10: Memantine (10 mg/kg)). 
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All experimental procedures were approved by the Animal Ethics Research Committee of the 
University of KwaZulu-Natal (Ethics approval number 075/11; 081/12) and were in accordance with 
the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH 
Publications No. 85-23, revised 1985). 
2.3. Drugs 
Apomorphine and memantine hydrochloride (Sigma-Aldrich, Missouri, USA) were dissolved in 
saline and injected subcutaneously and intraperitoneally respectively. Drug solutions were freshly 
prepared before each experiment. Control animals were injected with sterile saline (0.9% NaCl). 
2.4. Conditioned place preference paradigm 
Place conditioning was conducted in a two-compartment apparatus (23 × 23 × 23 cm3 each 
compartment) divided by a sliding partition. The compartments provided distinct contexts, with one 
compartment having horizontal and vertical white striped walls with a checked white pattern and 
net-like white mesh floor (A). The other compartment had black plain walls and a black plain smooth 
floor. The testing paradigm involved three phases [18]: 
(i) A pre-test phase: This phase took place on day one of the experiments, where each rat 
was placed individually into the apparatus for 15 min and was allowed free access to both 
compartments. The time spent in each compartment was recorded to determine the 
naturally preferred chamber for the animal. 
(ii) Conditioning phase: During five consecutive days, twice per day, animals were treated 
with apomorphine 1 mg/kg or saline 0.9% and subsequently paired with either the white 
or black compartment, where they were allowed to roam for 30 min [19,20]. The control 
group was paired with saline in both compartments while apomorphine-treated animals 
received saline in the preferred compartment and apomorphine in the less preferred 
compartment. This five-day schedule was repeated over a three-week period to induce 
place preference for apomorphine. During the third week, for five consecutive days, 
apomorphine-treated animals received saline 0.9% or memantine at 5 or 10 mg/kg [21], 
30 min prior to apomorphine injections in order to block the expression of CPP induced 
by apomorphine (Figure 1). 
(iii) Postconditioning: This phase was carried out on day 24, in a drug-free state. The animal 
was once again placed in the place preference apparatus and allowed free access to both 
compartments for 15 min. 
Conditioning scores were calculated as the time spent in the initially least preferred compartment. 
2.5. Tissue collection 
On day 24, animals were decapitated and their prefrontal cortex tissue was harvested, snap 
frozen in liquid nitrogen and stored in a bio-freezer at −75 °C. The tissue was later used for 
biochemical analysis. 
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2.6. Determination of glutamate receptor density in the frontal cortex using an enzyme-linked 
immunosorbent assay (ELISA) 
A commercially available rat glutamate receptor subunit zeta 1 (GRINL1A) ELISA kit 
(CUSABIO®) was used for the quantitative determination of glutamate receptor levels in frontal 
cortex of drug-treated and control animals. Twenty-five mg of rat prefrontal cortex tissue was rinsed, 
sonicated in 1 ml of phosphate-buffered saline, and stored overnight at −20 °C. After two freeze-thaw 
cycles were performed to rupture the cell membranes, the homogenates were centrifuged for 5 min at 
2000 x g, at 4 °C. Supernatants were removed and assayed immediately following the manufacture’s 
protocol. Basically, the protocol entailed preparation of the reagents, samples and standards as 
instructed in the protocol, addition of 100 µl standard or sample into each well (assay plate, 12 × 8 
coated microwells) to be incubated at 37 °C for 2 hrs. Liquid was then removed from each well and 
100 µl Biotin-antibody (1x) was added to the wells and incubated for an hour at 37 °C, this liquid 
was then removed through aspiration and the plate was washed three times with the wash buffer (200 µl) 
using a multi-channel pipette and was left to stand for 2 min followed by complete removal of the 
liquid by aspiration and inversion of the plate, blotting it on paper towel. One hundred µl of HRP-avidin 
was added to the wells and the plate was covered with an adhesive strip and again was incubated for 
an hour at 37 °C followed by the aspiration/wash process for five times. Ninety µl TMB Substrate 
was added to each well and the plate was covered with foil to protect it from light and incubated 
for 20 min at 37 °C. After this step was completed a Stop Solution was introduced to each well and 
the plate was gently tapped to ensure thorough mixing. The optical density of each well was 
subsequently determined within 5 min using a microplate reader that was set to 450 nm. 
2.7. Statistical analysis 
All results are reported as the mean ± SEM (standard error of mean). Data were analyzed using 
GraphPad Prism (version 5, San Diego, California, USA). The Shapiro-Wilk test revealed that the 
CPP data were normally distributed. A repeated measures ANOVA was used to examine memantine 
effects on apomorphine-induced CPP (pre- vs post-treatment), followed by the Bonferroni multiple 
comparison posthoc test. The NMDA receptor data were not normally distributed and as a result 
group differences in NMDA receptor levels were expressed as medians and interquartile range and 
analyzed by the Kruskal-Wallis test (non-parametric test) followed by Dunn’s multiple comparison 
test. The levels of statistical significance were set at p < 0.05. 
3. Results 
3.1. Effect of memantine on apomorphine-induced place preference 
As depicted in Figure 2, repeated measures ANOVA with time as repeated measure and 
treatment as factor revealed a significant treatment effect (F(9,80) = 10.55, p < 0.001). The 
Bonferroni test for differences between time spent in the apomorphine-associated compartment 
during the pre-treatment and post-treatment sessions showed no significant differences in saline (Sal) 
and memantine 5 mg (Mem5) treated groups (p > 0.05). However, a highly significant difference 
between time spent in the apomorphine-associated compartment during the pre- and post-treatment 
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sessions was revealed in animals undergoing chronic apomorphine treatment (p < 0.001) which 
suggests successful conditioning with apomorphine. The treatment of apomorphine-conditioned 
animals with memantine at 5 or 10 mg/kg did not change the time spent in the apomorphine-paired 
compartment (pre- vs post-treatment p = 0.0103 and p = 0.0332 respectively) suggesting that both 5 
and 10 mg/kg doses of memantine did not block the rewarding effects of apomorphine. 
 
Figure 2. Effect of memantine on apomorphine-induced place-preference in rats.Data are 
means ± S.E.M. **p < 0.01, ***p < 0.001, pre-conditioning vs post-conditioning  
(Bonferroni post hoc test) (n = 8 per group).Apo: apomorphine (1 mg/kg); Sal: saline 
(Nacl0.9%); Mem5: Memantine (5 mg/kg); Mem10: Memantine (10 mg/kg). 
3.2. Effect of memantine on prefrontal cortex NMDA receptor levels in animals undergoing chronic 
apomorphine treatment 
We further investigated glutamate NMDA receptor levels in the prefrontal cortex of rats treated 
with memantine and subjected to apomorphine-induced CPP (Figure 3). The non-parametric 
Kruskal-Wallis test revealed a main effect of treatment on NMDA receptor levels  
(p = 0.0045, n = 4 rats/group), Dunn’s multiple comparison test showed that chronic apomorphine 
treatment induced no significant effect compared to control group (p > 0.05), however memantine at 
5 mg/kg induced a significant increase in NMDA receptor density (p < 0.05). 
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Figure 3. Effect of memantine (Mem) on NMDA receptor levels in the prefrontal cortex 
of animals subjected to chronic apomorphine (Apo) treatment. The median was 832.5 
(interquartile range: 660.9–980.1) for Sal/Sal, 1136 (894–1390) for Sal/Mem5, 791.2  
(754.3–1019) for Apo/Sal, 1479 (1436–1629) for Apo/Mem5 and 1246 (1092–1478) 
Apo/Mem10. Data are presented as mean ± SEM. *p < 0.05 compared with control group 
(Sal/Sal) (Dunn’s Multiple comparison test) (n = 4 per group). 
4. Discussion 
This study assessed the potential anti-addictive effect of memantine in male rats undergoing 
chronic exposure to apomorphine, as well as the expression of NMDA receptors in the prefrontal 
cortex. Importantly, chronic exposure to apomorphine-induced CPP as expected but did not alter the 
expression of NMDA receptors. On other hands, memantine administered prior to apomorphine for 5 
days prior to testing, failed to block apomorphine-induced CPP. Memantine did, however, upregulate 
NMDA receptors in apomorphine-treated rats. 
Our results are consistent with previous behavioral studies indicating that apomorphine has 
reinforcing properties when administrated chronically at comparable doses (0.5, 1, 2.5 mg/kg) [22–24]. 
These properties are associated with direct stimulation of dopaminergic receptors D1 and D2 [5,23]. 
The effect of apomorphine, as well as all drugs of abuse, on the dopaminergic system, is usually 
paralleled by adaptive changes in the glutamatergic system [25,26]. These changes include increased 
responsiveness and expression of glutamatergic receptors, in particular, NMDA receptors expressed 
on dopaminergic neuron terminals in the prefrontal cortex [27]. Thus several studies suggested 
NMDA receptor antagonists as a potential treatment for the abuse of substances such as 
amphetamine, cocaine, and alcohol [15,28,29]. Indeed, NMDA receptor blockade has been shown to 
interfere with the development, maintenance and the expression of addiction-like behavior in animal 
models of morphine and alcohol addiction [30], However, under our experimental conditions, 
chronic exposure to apomorphine did not affect NMDA receptor levels in the prefrontal cortex which 
suggests that altered expression of NMDA receptors in the prefrontal cortex may not be a prominent 
feature of the conditioned response to apomorphine. Furthermore, it might be argued that the 
discrepancies between our study and previous findings could have been due to the duration of the 
treatment, or the duration of abstinence between the end of chronic treatment and behavioral testing. 
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Thus further studies on the effects of long-term apomorphine exposure in the corticostriatal pathways 
are needed to understand how changes in dopaminergic transmission may affect glutamatergic 
transmission to induce drug-seeking behavior. On the other hand, in accordance with the  
well-established effect of NMDA receptor antagonists in inducing NMDA receptor upregulation in 
animal models of drug addiction and in cultured cortical neurons [31], treatment with memantine 
increased NMDA receptors in the prefrontal cortex of apomorphine-conditioned rats but not in 
control rats. This may suggest that apomorphine treatment may have altered the glutamatergic 
system to make it more susceptible to the effects of memantine. Interestingly, this effect of 
memantine on NMDA receptor expression had no influence on apomorphine-induced CPP. The lack 
of effect of apomorphine on NMDA receptor levels in the prefrontal cortex is supported by the 
inability of memantine-induced up-regulation of NMDA receptors to alter apomorphine-seeking 
behavior. However, since memantine was absent during the first 2 weeks of conditioning as well as 
during memory recall in the post-treatment test of place preference, it may be possible that once CPP 
is established by apomorphine, manipulation of NMDA receptors by the administration of memantine 
has little consequence on drug-seeking behavior. It is noteworthy that the memantine-mediated increase 
in NMDA receptor levels also did not worsen drug-seeking behavior in animals that were treated 
with apomorphine. Thus, in contrast to the proposed therapeutic effect of NMDA receptor blockade 
by memantine [32–34], our study showed that up-regulation of the NMDA receptors by memantine 
after the establishment of CPP by apomorphine had minimal impact on the reversal of CPP. The fact 
that memantine did increase NMDA receptors in the prefrontal cortex indicates that its beneficial 
effects may be limited to certain specific circumstances only, such as the expression and 
maintenance of morphine, alcohol, and cocaine dependencies [35–37]. Our results, therefore, caution 
against the widespread use of memantine as a pharmacological intervention, especially in view of its 
ability to increase the number of NMDA receptors. Elevations in NMDA receptors could cause 
neural cells to be more vulnerable to glutamate excitotoxicity, since NMDA receptor up-regulation 
may result in an excessive entry of calcium, triggering a series of cytoplasmic and nuclear processes such 
as loss of mitochondrial membrane potential, which ultimately can lead to neuronal cell death [38]. 
Taken together, our data suggest that maintenance of apomorphine-induced CPP does not 
require upregulation of NMDA receptor expression in the prefrontal cortex, but may depend on 
indirect or compensatory mechanisms implicated in apomorphine-induced drug seeking. 
In conclusion, these findings provide further support for the drug-seeking-like effect of 
apomorphine and suggest that the prescription of memantine as a possible treatment for addiction 
must be done with caution. However, further studies are necessary to explore the functional 
consequences of memantine-induced increases in NMDA receptor expression. 
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